These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16234132)

  • 21. [New Drugs: Ectasy and Gamma-Hydroxy-Butyrate (GHB)].
    Feldman N; Croquette-Krokar M
    Vertex; 2002; 13(47):5-8. PubMed ID: 11967570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.
    Parrott AC; Buchanan T; Heffernan TM; Scholey A; Ling J; Rodgers J
    Psychopharmacology (Berl); 2003 Jun; 167(4):449-50. PubMed ID: 12682712
    [No Abstract]   [Full Text] [Related]  

  • 23. Loud noise enhances nigrostriatal dopamine toxicity induced by MDMA in mice.
    Gesi M; Ferrucci M; Giusiani M; Lenzi P; Lazzeri G; Alessandrì MG; Salvadorini A; Fulceri F; Pellegrini A; Fornai F; Paparelli A
    Microsc Res Tech; 2004 Jul; 64(4):297-303. PubMed ID: 15481049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users.
    Verheyden SL; Henry JA; Curran HV
    Hum Psychopharmacol; 2003 Oct; 18(7):507-17. PubMed ID: 14533132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of co-administration of 3,4-methylenedioxymethamphetamine ("ecstasy") or para-methoxyamphetamine and moclobemide at elevated ambient temperatures on striatal 5-HT, body temperature and behavior in rats.
    Stanley N; Salem A; Irvine RJ
    Neuroscience; 2007 Apr; 146(1):321-9. PubMed ID: 17306465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans.
    Liechti ME; Vollenweider FX
    Eur Neuropsychopharmacol; 2000 Jul; 10(4):289-95. PubMed ID: 10871712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Psychological aspects of MDMA (ecstasy) users].
    Varescon I
    Ann Med Interne (Paris); 2003 Nov; 154 Spec No 2():S81-5. PubMed ID: 14760230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
    de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
    J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are there sex differences associated with the effects of ecstasy/3,4-methylenedioxymethamphetamine (MDMA)?
    Allott K; Redman J
    Neurosci Biobehav Rev; 2007; 31(3):327-47. PubMed ID: 17109962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy").
    Cohen RS
    Biol Psychiatry; 1996 May; 39(9):819-20. PubMed ID: 8731525
    [No Abstract]   [Full Text] [Related]  

  • 31. 3,4-methylenedioxymethamphetamine (MDMA): a review.
    O'Leary G; Nargiso J; Weiss RD
    Curr Psychiatry Rep; 2001 Dec; 3(6):477-83. PubMed ID: 11707161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk.
    Silins E; Copeland J; Dillon P
    Aust N Z J Psychiatry; 2007 Aug; 41(8):649-55. PubMed ID: 17620161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The neuropsychology of ecstasy (MDMA) use: a quantitative review.
    Zakzanis KK; Campbell Z; Jovanovski D
    Hum Psychopharmacol; 2007 Oct; 22(7):427-35. PubMed ID: 17896346
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDMA and serotonin: based on two cases.
    Garcia Cabeza I; Zabala A; Soto-Montenegro ML; Arango C
    Actas Esp Psiquiatr; 2005; 33(5):339-42. PubMed ID: 16155817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypothyroidism alters striatal dopamine release mediated by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
    Peterson AL; Gilman TL; Banks ML; Sprague JE
    Synapse; 2006 Apr; 59(5):317-9. PubMed ID: 16421905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The new drugs: ecstasy, GHB. Update for practitioners].
    Feldman N; Croquette-Krokar M
    Rev Med Suisse Romande; 2001 Dec; 121(12):885-8. PubMed ID: 11803792
    [No Abstract]   [Full Text] [Related]  

  • 37. [Is the anxiety about Ecstasy justified?].
    Möller-Nehring E; Luderer HJ
    Fortschr Med; 1997 Mar; 115(7):28, 31-2, 34. PubMed ID: 9173018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mCPP: an undesired addition to the ecstasy market.
    Bossong MG; Brunt TM; Van Dijk JP; Rigter SM; Hoek J; Goldschmidt HM; Niesink RJ
    J Psychopharmacol; 2010 Sep; 24(9):1395-401. PubMed ID: 19304863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats.
    Clemens KJ; Cornish JL; Hunt GE; McGregor IS
    Drug Alcohol Depend; 2007 Jan; 86(2-3):183-90. PubMed ID: 16884865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence.
    McCann UD; Ricaurte GA
    J Clin Psychopharmacol; 1993 Jun; 13(3):214-7. PubMed ID: 8102623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.